Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Cipla
Fuji
Johnson and Johnson
Cerilliant
Farmers Insurance
Dow
Covington
Baxter

Generated: April 26, 2018

DrugPatentWatch Database Preview

Provensis Company Profile

« Back to Dashboard

What is the competitive landscape for PROVENSIS, and when can generic versions of PROVENSIS drugs launch?

PROVENSIS has one approved drug.

There are fourteen US patents protecting PROVENSIS drugs.

There are one hundred and sixty-nine patent family members on PROVENSIS drugs in thirty-nine countries.

Summary for Provensis
International Patents:169
US Patents:14
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Provensis

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes 8,323,677 ➤ Sign Up Y ➤ Sign Up
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes 7,357,336 ➤ Sign Up ➤ Sign Up
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes 7,604,185 ➤ Sign Up Y Y ➤ Sign Up
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes 8,122,917 ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Provensis

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,048,439 Therapeutic foam ➤ Sign Up
8,091,801 Generation of therapeutic microfoam ➤ Sign Up
7,763,269 Therapeutic foam ➤ Sign Up
9,545,378 Aerosol valve ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Queensland Health
Accenture
Express Scripts
Daiichi Sankyo
Cantor Fitzgerald
Moodys
McKinsey
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.